Skip to main content

Advertisement

Table 1 HPV prevalence and genotype distribution in women with and without cervical abnormalities

From: Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Author Area, subjects Study design HPV test HPV prevalence for any, HR*, LR** and specific genotypes among all tested womenaor only HPV positive womenb HPV prevalence and type specific genotypes among among all tested womenaor only HPV positive womenb by HIV status Comments
Population-Based studies
Serwadda et al., 1999 [52] Rakai district, Random sample of 960 women aged 15-59 years using self collected vaginal swabs Cross-sectional Hybrid Capture 2 Any HR-HPVa, 16.7% HIV status a
HIV+, 44.3%
HIV-, 10.2%
HIV prevalencea, 17.8%
Safaeian et al., 2007 [53] Rakai district, 606 women, median age 30 years (25-38 years) Baseline of a population-based cohort study Hybrid Capture 2/PGMY 09/11 assay Any HR-HPVa, 19%
Type-specific genotypes a
HPV 16, 4.5%
HPV 52, 4.4%
HPV 66, 3.0%
HPV 58, 3.0%
HIV status a
HIV positive
Self-collected, 40%
Physician collected, 37%
HIV negative
Self-collected, 15%
Physician collected, 16%
HIV prevalencea, 15.7%
Asiimwe et al., 2008 [21] Bushenyi district, 314 women with median age of 27 years (range,18-49) using self collected vaginal swabs Cross-sectional Hybrid Capture 2 assay Any HR-HPVa, 17.2%   HIV prevalencea, 5.6% (self-reported)
Safaeian et al., 2008b [20] Rakai district, 926 sexually exprienced women aged 15-49 years, mean age 26 years, who provided at least 3 consecutive self-collected swabs Population-based cross-sectional study Hybrid Capture 2/Prototype Roche reverse line blot assay Any HR-HPVa, 19.2%
Type-specific genotypes a
HPV 52, 2.2%
HPV 16, 2.1%
HPV 51, 1.7%
HPV 66, 1.5%
HPV 68, 1.3%
HIV status a
HIV+, 46.6%
HIV-, 14.8%
HIV prevalencea, 13.7%
Clinic-Based Studies
Adult women
Blossom et al., 2007 [17] STI clinic in Kampala, 106 women mean age 26.3 years (range,18-51) Cross-sectional Roche PCR/reverse strip assay Any HPVa, 46.2%
Type-specific genotypes b
HPV 16/18, 18.4%
HPV 52, 14.2%
HPV 16, 7.5%
HPV 58, 7.5%
Any HPV type a
HIV+, 59.5%
HIV-, 39.1%
HR-HPV types b
HIV+, 100.0%
HIV-, 88.9%
HIV prevalencea, 34.9%
Young women below 25 years
Banura et al., 2008a [16] Clinic for teenagers in Kampala, 1275 sexually active young women median age 20 years (range 12-24) Baseline of a cohort study SPF10/LIPA PCR assay Any HPVa, 74.6%
HR-HPV typesa, 51.4%
Type-specific genotypes a
HPV 52, 13.2%
HPV 51, 12.3%
HPV 18, 10.7%
HPV 16, 10.6%
LR-HPV typesa, 39.8%
LR-HPV genotypes a
HPV 6, 15.5%
HPV 11, 13.3%
HIV positive women
Any HPVa, 87.8%
HR-HPV types, 67.1%
Type-specific genotypes a
HPV 16, 18.3%
HPV 18, 9.8%
HPV 6, 15.9%
HPV 11, 17.1%
HIV negative women
Any HPVa, 73.2%
HR-HPV typesa, 49.7%
Type-specific genotypes a
HPV 16, 10.7%
HPV 18, 12.1%
HPV 6, 15.3%
HPV 11, 12.7%
HIV prevalencea, 8.6%
Banura et al., 2008b [18] Antenatal clinic in Kampala
987 young primiparous pregnant women, median age 19 years (range 14-24)
Baseline of a cohort study SPF10/LIPA PCR assay Any HPVa, 60.0%
High-risk typesb, 43.0%
Type-specific genotypes b
HPV 52, 12.1%
HPV 51, 8.7%
HPV 16, 8.4%
HPV 18, 5.8%
LR-HPV genotypes
LR-HPV typesb, 23%
Type-specific genotypes b
HPV 6, 5.5%
HPV 11, 3.2%
HIV positive women
Any HPVa, 72.2%
Type-specific genotypes b
HPV 16, 18.1%
HPV 18, 6.9%
HPV 6, 8.3%
HPV 11, 1.4%
HIV negative women
Any HPVa, 58.9%
Type-specific genotypes b
HPV 16, 7.7%
HPV 18, 5.7%
HPV 6, 5.3%
HPV 11, 3.4%
HIV prevalencea, 7.3%
Screened adult women
Buonaguro et al., 2000 [54] Nsambya hospital, Scrapes of 16 women with normal ecto-cervical epithelium and different degrees of cervical epithelial lesions Cross-sectional Southern Blot analysis HPV 16a, 12.5%   
Taube et al., 2010 [19] Post-natal clinic at Mulago hospital, Kampala
Cervical exfoliated cells from 196 women, 4-12 weeks post-partum and aged between 18-30 years (mean age for HIV -23 ± 3; HIV + 25.4 ± 3.2)
Cross-sectional Roche Linear array assay Any HR-HPVa, 49.0%
HPV 16/18a, 24%
HR-HPV types a
HPV 16, 8.2%
HPV 18, 3.5%
HPV 45, 5.1%
HPV 58, 5.1%
LR-HPV types a
HPV 6, 2.6%
HPV 11, 1.0%
HIV positive
Any HR-HPVa, 77.8%
Type-specific genotypes a
HPV 16, 13.9%
HPV 18, 5.6%
HPV 45, 8.3%
HPV 58, 5.6%
Other HR-HPV, 47.2%
LR-HPV types
HPV 6, 5.6%
HPV 11, 2.8%
HIV negative
Any HR-HPVa, 42.5%
Type-specific genotypes b
HPV 16, 6.9%
HPV 18, 3.1%
HPV 45, 4.4%
HPV 58, 5.0%
Other HR-HPV, 30.6%
HIV prevalencea, 18.0%
  1. *HR = High Risk; **LR = Low Risk
  2. a Denominator consist of all the tested women
  3. b Denominator consist of only HPV positive women